On Wednesday, Depomed Inc (NASDAQ:DEPO)’s shares inclined 0.23% to $21.62.
Depomed Inc (DEPO) declared that it will be presenting at The 2015 JMP Securities Life Sciences Conference in New York City. The presentation at the JMP conference is planned for 11:30 am EDT (8:30 am PDT) Wednesday, June 24, 2015.
Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the administration of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s shares gained 0.61% to $239.44.
Valeant Pharmaceuticals Intl Inc (VRX) and Progenics Pharmaceuticals, Inc. (PGNX) declared that the European Commission has approved RELISTOR(R) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. The decision effective May 27, 2015 is applicable to all 28 European Union member states plus Iceland and Norway and comprises an additional one year of marketing protection. The European Commission decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) which cited that RELISTOR offers a major contribution to patient care in comparison to existing therapies.
RELISTOR was first approved in Europe in 2008 for the treatment of OIC in advanced illness patients, and is presently approved in more than 50 countries counting the United States.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
At the end of Wednesday’s trade, Brookdale Senior Living, Inc. (NYSE:BKD)‘s shares dipped -0.64% to $37.46.
Brookdale Senior Living, Inc. (BKD) declared that administration will take part in a talk aboution regarding the Company at the Goldman Sachs 36th Annual Healthcare Conference in Los Angeles, California on Tuesday, June 9, 2015, startning at 10:40 a.m. Pacific Time.
Brookdale Senior Living Inc. owns and operates senior living communities in the United States. It operates through five segments: Retirement Centers, Assisted Living, Ongoing Care Retirement Communities (CCRCs)Rental, Brookdale Ancillary Services, and Administration Services.
Inventergy Global Inc (NASDAQ:INVT), ended its Wednesday’s trading session with 19.69% gain, and closed at $0.335.
SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, recently declared it has initiated coverage of Inventergy Global Inc. (INVT) with a Price Target of $1.03.
The report is accessible here: INVT Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will also be accessible on these platforms. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
Based in Campbell, CA, Inventergy is an intellectual property (IP) investment and licensing company. Inventergy works with leading technology companies to assist them attain greater monetization from their IP assets and let them focus on their core business operations. The IP monetization business has high margin potential for savvy patent owners, and Inventergy has deep expertise in the telecommunications industry, in particular, and is skilled at identifying, acquiring and licensing high quality patents.
Inventergy Global, Inc. operates as an intellectual property (IP) investment and licensing company. The company identifies, acquires, and licenses the patented technologies of technology companies. It offers a professional corporate licensing model for IP value creation that provides short term returns and long-term licensing revenue.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
